BioCryst's RAPIVAB (peramivir injection) Receives FDA Approval for a Pediatric Indication


BioCryst Pharmaceuticals, Inc. a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for RAPIVAB , an intravenous neuraminidase inhibitor, extending its availability for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days. The pediatric approval was based on the interim analysis of an ongoing pediatric clinical study.



from Biotech News